premarketdailyApellis Pharmaceuticals (APLS) surges 136% premarket on Biogen’s $5.6B acquisition — March 31, 2026
Apellis Pharmaceuticals (NASDAQ: APLS) rocketed 136% in premarket trading on Tuesday, March 31, 2026, after Biogen (BIIB) announced a definitive agreement to acquire the company for $41 per share in cash — approximately $5.6 billion upfront. The deal represents a 140% premium to
Apellis Pharmaceuticals (APLS) surges 136% premarket on Biogen’s $5.6B acquisition — March 31, 2026
Apellis Pharmaceuticals (NASDAQ: APLS) rocketed 136% in premarket trading on Tuesday, March 31, 2026, after Biogen (BIIB) announced a definitive agreement to acquire the company for $41 per share in cash — approximately $5.6 billion upfront. The deal represents a 140% premium to